Optimas Capital’s DexCom DXCM Stock Holding History

Optimas Capital’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-14,900	Closed	-$1.39M	–	45
2023 Q3	$1.39M	Buy	+14,900	New	+$1.68M	0.95%	27

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Optimas Capital's DXCM Position: Q4 2023 in Review

Optimas Capital sold out of DexCom (DXCM) in Q4 2023, closing a stake of 14,900 shares — an estimated $1.39M sold.

Optimas Capital first reported a position in DXCM in Q3 2023 and held it in 1 quarter. The position peaked at $1.39M in Q3 2023. 974 funds tracked by Wall St. Rank hold DXCM as of Q4 2023.

Optimas Capital reported no remaining DexCom position as of Q4 2023 after selling out during the quarter.
Optimas Capital sold 14,900 DexCom shares in Q4 2023, an estimated $1.39M.
Optimas Capital first reported a position in DexCom in Q3 2023 and held it in 1 quarter.
Optimas Capital's DexCom position peaked at $1.39M in Q3 2023.
974 funds tracked by Wall St. Rank held DexCom as of Q4 2023.

Based on Optimas Capital's 13F filing for Q4 2023, filed 23 Jan 2024.